- Home
- DRMA vs NUWE Comparison
DRMA vs NUWE Comparison
Compare DRMA & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- NUWE
- Stock Information
- Founded
- DRMA 2014
- NUWE 1999
- Country
- DRMA United States
- NUWE United States
- Employees
- DRMA N/A
- NUWE N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DRMA Health Care
- NUWE Health Care
- Exchange
- DRMA Nasdaq
- NUWE Nasdaq
- Market Cap
- DRMA 4.5M
- NUWE 3.9M
- IPO Year
- DRMA 2021
- NUWE N/A
- Fundamental
- Price
- DRMA $0.60
- NUWE $0.23
- Analyst Decision
- DRMA Strong Buy
- NUWE Strong Buy
- Analyst Count
- DRMA 1
- NUWE 1
- Target Price
- DRMA $3.00
- NUWE $17.00
- AVG Volume (30 Days)
- DRMA 94.5K
- NUWE 30.9M
- Earning Date
- DRMA 08-06-2025
- NUWE 08-12-2025
- Dividend Yield
- DRMA N/A
- NUWE N/A
- EPS Growth
- DRMA N/A
- NUWE N/A
- EPS
- DRMA N/A
- NUWE N/A
- Revenue
- DRMA N/A
- NUWE $8,787,000.00
- Revenue This Year
- DRMA N/A
- NUWE $6.53
- Revenue Next Year
- DRMA N/A
- NUWE $51.63
- P/E Ratio
- DRMA N/A
- NUWE N/A
- Revenue Growth
- DRMA N/A
- NUWE N/A
- 52 Week Low
- DRMA $0.57
- NUWE $0.21
- 52 Week High
- DRMA $5.00
- NUWE $6.61
- Technical
- Relative Strength Index (RSI)
- DRMA 29.24
- NUWE 26.12
- Support Level
- DRMA $0.57
- NUWE $0.21
- Resistance Level
- DRMA $0.63
- NUWE $0.32
- Average True Range (ATR)
- DRMA 0.04
- NUWE 0.07
- MACD
- DRMA -0.01
- NUWE 0.00
- Stochastic Oscillator
- DRMA 11.55
- NUWE 11.43
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.